Market Overview

Johnson & Johnson Wins New Trial In Talc Case

Johnson & Johnson Wins New Trial In Talc Case

An appeals court has ruled that a new trial is in order for Johnson & Johnson (NYSE: JNJ) after a jury ordered the company to pay $417 million to a woman who claims the company’s baby powder caused cancer, according to Bloomberg.

While there was was sufficient evidence to uphold the jury’s finding that Johnson & Johnson failed to warn Eva Echeverria about the health risks of using the baby powder, the court said there is conflicting evidence about the product’s cancer links, according to Wednesday's report. 

In May, Johnson & Johnson was ordered by a jury to pay $300 million in punitive damages to Donna Olson, who has mesothelioma.

Johnson & Johnson faces more than 14,000 claims that its talc powder caused ovarian cancer and mesothelioma, a rare cancer linked to asbestos exposure.

Trials over the cancer claims tied to Johnson & Johnson’s talc-based powders first began in 2016.

Johnson & Johnson shares were up 0.16% at $141.66 at the time of publication Wednesday. The stock has a 52-week high of $148.99 and a 52-week low of $121. 

Related Links:

Johnson & Johnson To Pay $300M In Punitive Damages In Olson Talc Cancer Case

Johnson & Johnson's Asbestos Woes: Experts Speak Up

Photo by Mattman723/Wikimedia

Posted-In: BloombergNews Legal Best of Benzinga


Related Articles (JNJ)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at